Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (115)	8/17/1998 1:58:00 AM
From: Vector1	Read Replies (2) \| Respond to of 666

PB and Christine, I have given the TAP program no value in my valuation of the company. They have not yet entered the clinic and with the discount applied to early stage products in the current environment is is unlikely to get much interest on from the street. The key to CLTR is Bexxar which IMO will be a blockbuster drug with potential for $500m in sales. The data that CLTR has made public is extraordinary. Median response time are approaching 3 years for relapsed and refactory patients who atain complete responses. WOW. These folks have about 8months on salvage CHOP with a horrific quality of life. Importantly the FDA recently approved an expanded access program for Bexxar with notably unrestrictive eligibility criteria. This approval not only is evidence that Bexxar will be approved for marketing in a timely manner, but also is significant in that it will enable Coulter to broadly "seed" the market prior to launch. V1